| 刘宏达,邵祥忠,李林,许小伟.CYP2C19基因多态性对高危非致残性缺血性脑血管事件患者抗血小板治疗预后的影响.[J].中南医学科学杂志.,2023,(6):938-941. |
| CYP2C19基因多态性对高危非致残性缺血性脑血管事件患者抗血小板治疗预后的影响 |
| The effect of CYP2C19 gene polymorphism on the prognosis of antiplatelet therapy in high-risk patients with non-disabling ischemic cerebrovascular events |
| 投稿时间：2022-09-05 修订日期：2023-08-12 |
| DOI：10.15972/j.cnki.43-1509/r.2023.06.034 |
| 中文关键词: HR-NICE CYP2C19基因 抗血小板治疗 预后 [ |
| 英文关键词:HR-NICE CYP2C19 gene antiplatelet therapy prognosis |
| 基金项目:南通市科技局社会民生科技计划项目(MSZ19052) |
|
| 摘要点击次数: 169 |
| 全文下载次数: 105 |
| 中文摘要: |
| 目的探讨CYP2C19基因多态性对高危非致残性缺血性脑血管事件(HR-NICE)患者抗血小板治疗预后的影响。 方法选取HR-NICE患者120例,按CYP2C19基因检测结果分为慢代谢型组40例、中代谢型组36例、快代谢型组44例,均行抗血小板药物治疗。比较各组血小板集聚及不良预后情况,Logistic回归分析影响预后的危险因素。 结果与治疗前比较,治疗后中代谢型组、快代谢型组血小板聚集率下降,且中代谢型组、快代谢型组低于慢代谢型组,快代谢型组低于中代谢型组(P＜0.05)。快代谢型组再次缺血性脑卒中发生率低于慢代谢型组和中代谢型组(P＜0.05)。Logistic回归分析发现,男性、糖尿病、CYP2C19基因慢代谢型、中代谢型是影响HR-NICE患者预后的独立危险因素；而CYP2C19基因快代谢型是影响HR-NICE患者预后的保护因素(P＜0.05)。 结论CYP2C19基因对HR-NICE患者抗血小板治疗具有指导作用；CYP2C19基因慢代谢型、中代谢型可能是影响患者预后的危险因素。 |
| 英文摘要: |
| AimTo investigate the effect of CYP2C19 gene polymorphism on the prognosis of antiplatelet therapy in high-risk patients with non-disabling ischemic cerebrovascular events (HR-NICE). Methods120 HR-NICE patients were selected and divided into a slow metabolic group of 40 cases, a medium metabolic group of 36 cases, and a fast metabolic group of 44 cases, based on the CYP2C19 gene detection results. All patients received antiplatelet therapy. The platelet aggregation and poor prognosis among different groups were compared, and the risk factors affecting prognosis were analyzed through Logistic regression analysis. ResultsCompared with before treatment, the platelet aggregation rate in the middle and fast metabolism groups decreased after treatment, and the middle and fast metabolism groups were lower than the slow metabolism group, while the fast metabolism group was lower than the middle metabolism group (P＜0.05). The incidence of recurrent ischemic stroke in the fast metabolism group was lower than that in the slow metabolism group and the medium metabolism group (P＜0.05). Logistic regression analysis showed that male, diabetes, CYP2C19 slow metabolism type and middle metabolism type were independent risk factors affecting the prognosis of HR-NICE patients. The fast metabolic type of CYP2C19 gene is a protective factor for the prognosis of HR-NICE patients (P＜0.05). ConclusionThe CYP2C19 gene has a guiding role in antiplatelet therapy for HR-NICE patients. CYP2C19 gene slow and moderate metabolic types may be risk factors affecting patient prognosis. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|